On Thursday, May 28, 2026, after years of delay, the Departments of Labor, the Treasury, and Health and Human Services through the Centers for Medicare & Medicaid Services issued a final rule for the No Surprises Act (“NSA”), implementing major reforms intended to improve the functioning of the NSA’s independent dispute resolution (“IDR”) process.

The NSA was enacted in December 2020 and largely went into effect on January 1, 2022. Intended to prevent “surprise” medical bills generated when a patient is treated by out-of-network providers at in-network medical facilities, the NSA instituted a two-step IDR framework to resolve payment disputes between health insurers (or “payors”) and providers. Under this framework, the parties first began with a 30-business-day open negotiation period intended to provide payors and providers with an opportunity to agree on an appropriate payment rate without beginning the formal IDR process. Upon expiration of this open negotiation period, the dispute proceeded to arbitration conducted by a certified Independent Dispute Resolution Entity, which considered multiple statutory factors before selecting between the payor and provider’s proposed payment amounts for the claim.

This process led to complications. Since the IDR process first launched in April 2022, the federal government has reported that it has received far more disputes than initially anticipated—more than 5 million. The sheer volume created long delays and unnecessary costs. The federal government’s final rule aims to tackle these inefficiencies and operational challenges.

The Final Rule

Against this backdrop, the final rule addresses the operational bottlenecks plaguing the IDR system since its inception. Specifically, the final rule creates a series of reforms intended to reduce ineligible claims, lower costs, and improve communication between payors and providers.

Greatly Reduced Administrative Fees

The final rule dramatically reduces the administrative fees for participation in the IDR process. Fees have been cut nearly 75%—from $115 per party per dispute to $15. This fee reduction will be applicable to disputes initiated on or after June 4, 2026, representing five business days after the publication of the final rule.

Improved Communications when Beginning Disputes

When initiating the dispute process under the NSA, payors send providers either an initial payment or denial of payment in response to a submitted claim subject to the NSA. Payors are required to disclose the qualifying payment amount (“QPA”) of the claim, as well as contact information to initiate the open negotiation period. The final rule has instituted a requirement for payors to communicate this information to providers using particular codes (claim adjustment reason codes, or “CARCs,” and remittance advice remark codes, or “RARCs”) to indicate whether the claim is or is not subject to the NSA’s surprise billing provisions and the Federal IDR process. Payors will also be required to provide additional information. This standardization is anticipated to ultimately reduce the number of ineligible payment disputes submitted through the IDR process.

Streamlining of Open Negotiation Period

The federal government also created new rules pertaining to the NSA’s 30-business-day open negotiation period, with the goal of promoting more meaningful engagement during negotiations and allowing the parties to agree on an appropriate rate of payment without escalating to the IDR process. These changes require parties to provide notice to the other parties and to the federal government that the open negotiation period has begun, as well as specify that the open negotiation period begins on the date when a party submits that notice. These changes are intended to provide certainty regarding whether and when the open negotiation period has begun and that its start and end dates are thoroughly documented to the federal government.

Clarity on Batching Claims

The NSA allows parties to include multiple claims in a single “batched” dispute. The final rule places additional limits and flexibilities on the size and content of batched disputes, allowing claims to be batched where (1) they are furnished to a single patient on the same or consecutive dates of service and billed on the same claim form; (2) they are furnished to one or more patients and are billed under the same or comparable service codes; (3) they are certain specialty items or services that are furnished to one or more patients under codes belonging to the same Category I CPT code sections.

IDR Eligibility

Citing the resource-intensive and time-consuming work associated with IDR eligibility determinations impeding the timely resolution of payment disputes, the federal government also instituted a requirement that IDR entities making these determinations do so within 5 business days of their selection. Parties are also required to submit additional information to the IDR entities within 5 business days of any request for additional information.

IDR Registry

The final rule also establishes a new IDR Registry, which requires payors subject to the IDR process to register with the federal government to provide certain general information on the application of the IDR process to items and services covered by their plans. Providing this information will streamline the process for providers to identify the correct party involved in a dispute and avoid unnecessary disputes. The rule contemplates a new, centralized IDR Gateway platform which will allow users to begin disputes and track their status in one location. The Gateway is expected to launch in phases beginning in 2026.

Impact on Ongoing Litigation Surrounding the NSA

This final rule arrives against a backdrop of extensive litigation surrounding the NSA and its implementation. Several categories of disputes have emerged. While the final rule may assist in resolving challenges pertaining to IDR process integrity by providing more thorough guardrails, such as payor-initiated challenges that Proskauer reported on here, significant litigation surrounding the enforceability of IDR awards remains unresolved.

The question of whether the NSA has a private cause of action allowing providers to enforce IDR awards when payors fail to pay is perhaps the most consequential trend in NSA litigation. The NSA limits judicial review of IDR awards to narrow circumstances outlined in the Federal Arbitration Act (“FAA”). As Proskauer previously reported here, here, here, and here, there is a deepening circuit split regarding whether the FAA applies to enforce these awards. On the one hand, federal district courts in New York and Florida, as well as the Fifth Circuit, have held that there is no private right of action to enforce IDR awards, leaving providers with favorable IDR awards facing non-payment from payors to rely on administrative complaint processes. On the other hand, the federal district courts in Connecticut, Maryland, and New Jersey have held that the FAA provides a mechanism to confirm NSA awards. The Supreme Court recently denied a petition for certiorari to review the Fifth Circuit’s determination that the FAA provides no private right of action, allowing this divide to stand.

Under the Fifth Circuit’s reasoning, NSA IDR awards are treated as subject to judicial enforcement under the FAA where a court is considering vacating an IDR award but not enforcing one. While providers suing payors to enforce IDR awards may be turned away for lack of a private right of action, payors suing providers and IDR administrators are, concurrently, having little luck using the courts to vacate unfavorable IDR awards under the NSA. Thus far, courts in California and Florida have dismissed with prejudice payors’ claims for vacatur.

Next Steps

While the final rule clarifies and streamlines the IDR process in the hopes of easing the bottleneck of outstanding IDR disputes, it remains unclear whether these steps will lower the number of disputes proceeding to IDR. While claims eligibility clarifications may reduce this number, the massive reduction in filing fees has the potential to offset this reduction. The foregoing notwithstanding, the final rule sheds no additional light on one of the most pressing issues surrounding the implementation of the NSA: its ability to effectively enforce—or vacate—payment of IDR awards.

The final rule is available here. A CMS fact sheet summarizing these changes is available here.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Matthew J. Westbrook Matthew J. Westbrook

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others.

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others. Matt specifically provides advice on fraud and abuse matters arising under the Federal False Claims Act (FCA), Civil Monetary Penalties Law, Federal Anti-Kickback Statute (AKS), and Physician Self-Referral Law (Stark Law), as well as on the regulations promulgated by the Drug Enforcement Administration (DEA) and the Department of Health and Human Services, including the Office of Inspector General (OIG), Centers for Medicare & Medicaid Services (CMS), and Food and Drug Administration (FDA).

Before joining the Firm, Matt served as senior counsel in OIG’s Administrative and Civil Remedies Branch. At OIG, Matt was responsible for determining whether to impose administrative sanctions, including civil money penalties and Federal health care program exclusions, against health care providers and suppliers, and whether to impose civil money penalties on hospitals and physicians in connection with matters referred to CMS under the Emergency Medical Treatment and Labor Act (EMTALA). During his tenure, Matt also litigated exclusion appeals before administrative law judges and appellate panels of the Departmental Appeals Board; advised United States Attorney’s Offices on exclusions appealed to Federal district courts; resolved voluntary self-disclosures submitted by providers and grant and contract recipients; and participated in the negotiations and settlements of FCA matters by the Department of Justice involving the AKS, Stark Law, CMS reimbursement issues, and DEA and FDA compliance issues. In connection with certain FCA resolutions, Matt also negotiated and monitored corporate integrity agreements.

On the Florida junior circuit and in college, Matt was a competitive tennis player. Matt played on the varsity team and was captain his senior year at Rhodes College, earning ITA Division III and SCAC All-Academic Honor Roll awards his sophomore, junior, and senior years. Matt is an active member of the American Health Law Association (AHLA) and currently serves as a Vice Chair of AHLA’s Fraud and Abuse Practice Group.

Articles:

Matthew J. Westbrook and David M. Blank, “Using OIG’s Cross-Component Audit and Enforcement Data to Strengthen Your Compliance Program,” Compliance Today (February 2024).

Ed Kornreich, Matthew Westbrook, and Angela Gichinga, “Bracing for the Impact of the No Surprises Act,” Westlaw Today (June 16, 2022).

Presentations:

Bill Mathias and Matt Westbrook, “‘Lightning Round’:  A Fraud & Abuse Due Diligence Game Show,” American Health Law Association (Health Care Transactions Conference, May 5–6, 2025).

Matthew J. Westbrook and David M. Blank, “Recent Trends in CMPL Enforcement, American Health Law Association (Webinar, May 24, 2023).

Photo of Vinay Kohli Vinay Kohli

Vinay Kohli is a healthcare industry lawyer.  Recognized for his focus and commitment to the healthcare industry, a wide range of healthcare businesses use Vinay as an outside general counsel to guide them on strategic planning, compliance matters, operational questions, and reimbursement concerns. …

Vinay Kohli is a healthcare industry lawyer.  Recognized for his focus and commitment to the healthcare industry, a wide range of healthcare businesses use Vinay as an outside general counsel to guide them on strategic planning, compliance matters, operational questions, and reimbursement concerns.  He provides regulatory, compliance, and reimbursement advice on topics that range from venture formation, technology implementation, and risk management to day-to-day contract negotiations.

Vinay’s background is unique in that he is also a seasoned trial lawyer.  He is able to combine his regulatory expertise with a trial lawyer skillset for jury trials, bench trials, and arbitrations arising in the healthcare arena—he represents hospital systems, physician practices, providers of post-acute care services, as well as healthcare technology and revenue cycle management companies. He defends health care fraud and abuse litigation, prosecutes managed care disputes against large national payors, and handles government investigations.  And clients frequently call upon Vinay to serve as lead trial counsel in commercial litigation disputes that span the gamut from breach of contract and trade secret misappropriation to unfair business practices and breach of fiduciary claims.

Vinay received his B.B.A., magna cum laude, M.A., and J.D. from the University of Texas at Austin in 2005, 2006, and 2009 respectively.

Prior to joining Proskauer, Vinay was a partner in the Healthcare group at King & Spalding.

Photo of Devin Cohen Devin Cohen

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters.

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters. He has a deep understanding of both deal mechanics and the evolving regulatory landscapes in the areas of strategic investment, vertical integration, insurance and brokerage, as well as research.

Over the course of his career, Devin has advised a wide range of health care organizations and investors on value-based care arrangements and initiatives, and routinely advises insurers and providers to structure collaborative care models and Medicare Advantage. In addition, Devin has worked with clients on matters related to pharmaceutical and medical device research and development and clinical trials, including fraud and abuse considerations, human subject protections requirements, animal welfare standards, sponsored and investigator-initiated research negotiations, and compliance monitoring.

Clients value Devin’s responsiveness, as well as his ability to cut through complexity to provide clear, actionable guidance. They also appreciate the strong people skills he brings to the table, which are particularly helpful in negotiations.

Devin’s passion for health care extends to his community service and pro bono efforts in the Boston area. He works with Heading Home and other non-profits providing shelter to those in need throughout the Commonwealth of Massachusetts, among others.

Devin joins Proskauer from Ropes & Gray LLP where he was a partner in the firm’s Health Care practice.

Experience

Devin regularly works with a wide range of health care organizations — including physician groups, academic medical centers, clinical networks, hospitals, dental and management services organizations, insurers, brokers/agents, pharmaceutical and medical device manufacturers, and provider organizations — as well as industry investors, across areas such as:

Health care transactions and investments

  • Provide transactional and regulatory counsel to providers and investors. Examples include:
  • Assisted multiple regional health plans in their mergers and acquisitions of new plans to expand insurance product offerings.
  • Advised a private equity firm on its investment in an online insurance brokerage platform.
  • Counsel investors on emerging state health care transaction laws, corporate practice of medicine, and MSO/DSO structuring.
  • Advise multiple private sponsors on CRO and SMO investments

Value-based care arrangements

  • Counsel a wide range of providers, payors, practice management organizations, vendors and industry investors in the areas of Medicare Advantage, CMMI program participation, state risk-bearing implications and insurance requirements.
  • Advise on strategic partnerships and joint ventures, including innovative collaborations aimed at expanding access to value-based primary care for Medicare beneficiaries.

Regulatory and compliance

  • Routinely counsel Medicare Advantage Organizations, FDRs and program vendors on Medicare Advantage regulatory and contracting standards.
  • Advise investors and brokers/agencies on emerging Medicare requirements, including emerging standards related to sales commissions payments.
  • Advise medical device and pharmaceutical manufacturers on regulatory standards related to customer and patient interactions, marketing and clinician education standards, industry and jointly sponsored CME, patient assistance programs, and related compliance program requirements.

Clinical research and related activities

  • Regularly provide guidance on drug and drug component development/commercialization considerations for sites, investigators and sponsors.
  • Routinely advise institutional and start-up manufacturers, as well as CROs and trial sites, on cutting-edge clinical trial contracting negotiations.
  • Provide counsel on research affiliation agreements, including advising a large academic medical center on developing and implementing its research affiliation agreement with a local pediatric health network.
  • Conduct regulatory diligence for private equity clients regarding their planned investments in companies that participate in the clinical research enterprise.
  • Advise academic medical centers on research misconduct matters.